Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation
Open Access

Hybrid 18F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases

Nathaniel J. Smith, Tristan K. Deaton, Wendy Territo, Brian Graner, Andrew Gauger, Scott E. Snyder, Michael L. Schulte, Mark A. Green, Gary D. Hutchins and Michael C. Veronesi
Journal of Nuclear Medicine April 2023, jnumed.122.265149; DOI: https://doi.org/10.2967/jnumed.122.265149
Nathaniel J. Smith
1School of Medicine, Indiana University, Indianapolis, Indiana;
2Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tristan K. Deaton
3Indiana University–Purdue University, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Territo
1School of Medicine, Indiana University, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Graner
1School of Medicine, Indiana University, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Gauger
1School of Medicine, Indiana University, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott E. Snyder
1School of Medicine, Indiana University, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael L. Schulte
1School of Medicine, Indiana University, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Green
1School of Medicine, Indiana University, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary D. Hutchins
1School of Medicine, Indiana University, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael C. Veronesi
1School of Medicine, Indiana University, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.122.265149
DOI 
https://doi.org/10.2967/jnumed.122.265149
PubMed 
37116915

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication November 16, 2022
  • Revision received February 16, 2023
  • Published online April 28, 2023.

Article Versions

  • You are currently viewing a previous version of this article (April 28, 2023 - 06:08).
  • View the most recent version of this article
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

  1. Nathaniel J. Smith1,2,
  2. Tristan K. Deaton3,
  3. Wendy Territo1,
  4. Brian Graner1,
  5. Andrew Gauger1,
  6. Scott E. Snyder1,
  7. Michael L. Schulte1,
  8. Mark A. Green1,
  9. Gary D. Hutchins1 and
  10. Michael C. Veronesi1
  1. 1School of Medicine, Indiana University, Indianapolis, Indiana;
  2. 2Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana; and
  3. 3Indiana University–Purdue University, Indianapolis, Indiana
  1. For correspondence or reprints, contact Michael Veronesi (michael.veronesi{at}gmail.com).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 10 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • 18F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma
    Begoña Manzarbeitia-Arroba, Marina Hodolic, Robert Pichler, Olga Osipova, Ángel Maria Soriano-Castrejón, Ana María García-Vicente
    Cancers 2023 16 1
  • Hybrid18F-FET PET and Perfusion MRI to Differentiate Disease Progression from Treatment-Related Changes in Malignant Brain Tumors
    Norbert Galldiks, Karl-Josef Langen
    Journal of Nuclear Medicine 2023 64 7
  • Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment
    John Rafanan, Nabih Ghani, Sarah Kazemeini, Ahmed Nadeem-Tariq, Ryan Shih, Thomas A. Vida
    International Journal of Molecular Sciences 2025 26 3
  • PET Imaging of Metabolism, Perfusion, and Hypoxia
    Austin R. Pantel, Seong-Woo Bae, Elizabeth J. Li, Sophia R. O'Brien, H. Charles Manning
    The Cancer Journal 2024 30 3
  • An effective MRI perfusion threshold based workflow to triage additional 18F-FET PET in posttreatment high grade glioma
    Krishna Ranjith Kadali, Nathalie Nierobisch, Fabienne Maibach, Philip Heesen, Paula Alcaide-Leon, Martin Hüllner, Michael Weller, Zsolt Kulcsar, Nicolin Hainc
    Scientific Reports 2025 15 1
  • Borderline Findings inO-(2-[18F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice
    Karl-Josef Langen, Gabriele Stoffels, Christian P. Filss, Martin Kocher, Christoph Lerche, Michael Sabel, Marion Rapp, Hosai Noltemeier, Jan-Michael Werner, Garry Ceccon, Michael M. Wollring, Jurij Rosen, Joachim P. Steinbach, Elke Hattingen, Martin R. Weinzierl, Michael Stoffel, Hans Clusmann, N. Jon Shah, Felix M. Mottaghy, Norbert Galldiks, Philipp Lohmann
    Journal of Nuclear Medicine 2025 66 2
  • Comparing the diagnostic performance of DSC-MRI and FAPI PET in differentiating tumor progression from treatment-related changes in IDH-Wildtype Glioblastoma: A pilot study
    Hasan Önner, Halil Özer, Burak Gezer, Kazım Muslu Körez, Hakan Cebeci, Orhan Önder Eren, Ender Köktekir, Hakan Karabağlı
    European Journal of Radiology 2025 187
  • Development and validation of a HPLC method for the determination of chemical and radiochemical purity of O-(2-[18F]fluoroethyl- -tyrosine ([18F]FET)), a PET radiotracer for the imaging of brain tumor
    Min Wang, Chase A. Arkins, Qi-Huang Zheng, Barbara Glick-Wilson, Scott Snyder
    Applied Radiation and Isotopes 2024 212
  • Introducing the American Society of Neuroradiology PET-Guided Diagnosis and Management in Neuro-Oncology Study Group
    A. Nabavizadeh, N. Galldiks, M. Veronesi, P. Lohmann, J.E. McConathy, D.R. Johnson, M.S. Aboian, R.F. Barajas, J. Ivanidze
    American Journal of Neuroradiology 2024 45 5
  • Nuclear Medicine Hybrid Imaging for Radiographers & Technologists
    Maria Agnese Pirozzi, Anna Prinster
    2025

Article usage

Article usage: April 2023 to April 2025

AbstractFullPdf
Apr 202312831839
May 2023510392113
Jun 202316720371
Jul 2023469673116
Aug 202314947078
Sep 20238032054
Oct 20236617244
Nov 20238216332
Dec 2023198533
Jan 20246419845
Feb 20242524131
Mar 20243215828
Apr 20241610833
May 20242312826
Jun 2024199828
Jul 2024199035
Aug 2024245021
Sep 2024164327
Oct 2024206237
Nov 2024146126
Dec 2024227530
Jan 202596918
Feb 20251811032
Mar 20251311441
Apr 2025189452
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hybrid 18F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Hybrid 18F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
Nathaniel J. Smith, Tristan K. Deaton, Wendy Territo, Brian Graner, Andrew Gauger, Scott E. Snyder, Michael L. Schulte, Mark A. Green, Gary D. Hutchins, Michael C. Veronesi
Journal of Nuclear Medicine Apr 2023, jnumed.122.265149; DOI: 10.2967/jnumed.122.265149

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Hybrid 18F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
Nathaniel J. Smith, Tristan K. Deaton, Wendy Territo, Brian Graner, Andrew Gauger, Scott E. Snyder, Michael L. Schulte, Mark A. Green, Gary D. Hutchins, Michael C. Veronesi
Journal of Nuclear Medicine Apr 2023, jnumed.122.265149; DOI: 10.2967/jnumed.122.265149
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Borderline Findings in O-(2-[18F]-Fluoroethyl)-L-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice
  • Introducing the American Society of Neuroradiology PET-Guided Diagnosis and Management in Neuro-Oncology Study Group
  • Google Scholar

More in this TOC Section

  • 177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial
  • Transarterial Radioembolization in the TACOME Trial: Dosimetric Analysis and Clinical Features in Predicting Response and Overall Survival
  • Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice
Show more Clinical Investigation

Similar Articles

Keywords

  • malignant brain tumors
  • WHO CNS grade 3 or 4 glioma
  • Glioblastoma
  • brain metastasis
  • amino acid PET
  • 18F-fluoroethyltyrosine (FET) PET
SNMMI

© 2025 SNMMI

Powered by HighWire